Federal procurement of unlicensed medicines in Brazil; findings and implications-Reference-Cited by-同舟云学术

Federal procurement of unlicensed medicines in Brazil; findings and implications

Published:2017-04-13 Issue:6 Volume:17 Page:607-613
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Teodoro Cristiane Roberta dos Santos¹,Caetano Rosângela²,Godman Brian³⁴⁵,dos Reis André Luís Almeida⁶,Maia Aurélio de Araújo⁷,Ramos Mariana de Carvalho Barbosa⁷,Osorio-de-Castro Claudia Garcia Serpa¹

Affiliation:

1. Department of Pharmaceutical Policies and Pharmaceutical Services, Sergio Arouca National School of Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

2. Social Medicine Institute, Rio de Janeiro State University, Rio de Janeiro, Brazil

3. Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK

4. Division of Clinical Pharmacology, Karolinska Institutet, Stockholm, Sweden

5. Liverpool Health Economics Centre, University of Liverpool Management School, Liverpool, UK

6. Coordination of Intellectual Property, Brazilian National Regulatory Agency (ANVISA), Rio de Janeiro, Brazil

7. Department of Health Economics, Investment and Development, Executive Secretariat, Brazilian Ministry of Health, Brasília, Brazil

Funder

Brazilian Research and Development Council

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2017.1311209

Reference32 articles.

1. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

2. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

3. Dabigatran: how the drug company withheld important analyses

4. Examples of how the pharmaceutical industries distort the evidence of drug safety: the case of pioglitazone and the bladder cancer issue

5. Brasil. Lei Federal n° 6.360, de 23 de setembro de 1976. Diário Oficial da União 1976. [Federal Law number 6360, Sept 23 1976. Brazilian National Gazette 1976]. Portuguese. 1976. [cited 2016 Mar 16]. Available from: www.planalto.gov.br/ccivil_03/leis/l6360.htm

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A lacuna regulatória de medicamentos órfãos impacta na disponibilidade de alternativas terapêuticas no Brasil?;Revista Colombiana de Ciencias Químico-Farmacéuticas;2022-10-29

2. Data Sources for Drug Utilization Research in Brazil—DUR-BRA Study;Frontiers in Pharmacology;2022-01-14

3. Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort;PLOS ONE;2021-11-08

4. The quality of research on judicialization and its influence on public policies on access to medicines in Brazil: a systematic review;Ciência & Saúde Coletiva;2021-11

5. Towards a taxonomy of judicialisation for access to medicines in Latin America;Global Public Health;2021-03-02